Sponsor:
Pleryon Therapeutics (Hangzhou) Limited
Code:
NCT07593404
Conditions
Dry Eye Syndrome (DES)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Part 2 ABR2 At least twice a day for 28 days
Part 1: ABR2 single dose in one eye
Brief summary:
Conditions
Dry Eye Syndrome (DES)
Study ID
NCT07593404
Start date
May, 2026
Status verified date
May, 2026
Completion date
May, 2027
Anticipated
Primary completion date
Jan, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
40 participants
Anticipated
Allocation
Non randomized
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Part 1
experimental: Part 2
Interventions
Part 2 ABR2 At least twice a day for 28 days
Part 1: ABR2 single dose in one eye
Primary outcome measure
Central contacts
Locations
Centre for Ocular Research & Education, School of Optometry & Vision Science, University of Waterloo
Recruiting
Waterloo, Ontario, Canada, N2L 3G1
Contacts
Principal Investigator:
Jill Woods, MSc, MCOptom
Sponsor
Pleryon Therapeutics (Hangzhou) Limited
Last update posted
May 19, 2026
Last verified
May, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Pleryon Therapeutics (Hangzhou) Limited on 2026-05-19.